Atezolizumab

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC 4:40
IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC
Aris Bamias
PRS-343 in HER2-Positive Solid Tumors: A trial update 3:11
PRS-343 in HER2-Positive Solid Tumors: A trial update
Geoffrey Ku
Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more 3:50
Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more
Aditya Bardia
PRINCEPS study: atezolizumab for resectable NSCLC 3:30
PRINCEPS study: atezolizumab for resectable NSCLC
Benjamin Besse
Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8 3:11
Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8
Isabelle Ray-Coquard
NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer 4:22
NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer
Giampaolo Bianchini
ESMO highlights: genitourinary cancers 3:49
ESMO highlights: genitourinary cancers
Yann-Alexandre Vano
Systemic therapies for advanced HCC 5:44
Systemic therapies for advanced HCC
Arndt Vogel
Updates from IMbrave 150 in HCC 4:05
Updates from IMbrave 150 in HCC
Daneng Li
Novel developments in HCC treatment 3:56
Novel developments in HCC treatment
Daneng Li
ESMO WCGIC: highlights in HCC 3:33
ESMO WCGIC: highlights in HCC
Ghassan Abou-Alfa
Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer 5:42
Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer
Michael Morris
IMvigor010: atezolizumab for UC 3:43
IMvigor010: atezolizumab for UC
Thomas Powles
Personalizing immunotherapy beyond PDL1 expression 7:09
Personalizing immunotherapy beyond PDL1 expression
Marleen Kok
The right biomarker for the right patient 17:02
The right biomarker for the right patient
Nicola Fusco
GELATO: carboplatin and atezolizumab in advanced lobular BC 3:53
GELATO: carboplatin and atezolizumab in advanced lobular BC
Leonie Voorwerk
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals